NCT00702403 · REGISTRY CONDITION SEARCH

Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: PHASE1, PHASE2
Status at capture: COMPLETED
Registry last update: 2017-08-10

This phase I/II trial is studying the side effects and best way to give nilotinib when given alone or sequentially after imatinib mesylate after donor stem cell transplant in treating patients with acute lymphoblastic leukemia or chronic myelogenous leukemia. Nilotinib and imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Number of Participants With Treatment Safety Failure

→

outcome · POSTED

The Proportion of Patients at 1 Year With Treatment Efficacy Success

→

outcome · POSTED

Survival

→

outcome · POSTED

Patients Alive With Out Relapse

→

outcome · POSTED

Relapse

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Inclusion Criteria: * Body surface area \>= 1 m\^2 * Allogeneic HCT * Acute lymphocytic leukemia (ALL) or chronic myelogenous leukemia (CML) characterized by the p190 and/or p210 BCR/ABL gene rearrangement * CML in accelerated phase, blast crisis, or blast crisis remission as defined by World Health Organization (WHO) criteria * CML in chronic phase if patient age =\< 17 years or a patient of any age with CML in second chronic phase or beyond * Patients with minimal residual disease (MRD) that is not declining in response to tyrosine kinase inhibitor therapy must be screened for the T315I and other mutations * An appropriately matched related or unrelated donor * Signed informed consent * Patient must have a life expectancy of at least 2 months * Stated willingness of the patient to comply with study procedures and reporting requirements * Creatinine =\< 2.0 x upper limit normal (ULN) * Platelets \> 20 x 10\^9 /L * Serum aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =\< 3 x ULN, conjugated bilirubin \< 3 x ULN * Serum potassium phosphorus, magnesium, and calcium \>= lower limit normal (LLN) or correctable with supplements prior to first dose of study drug; calcium levels may be corrected for hypoalbuminemia * Serum amylase and lipase \< 1.5 x ULN * Female patients of childbearing potential must have negative pregnancy test within 7 days before initiation of study drug dosing; postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential; male and female patients of reproductive potential must agree to employ an effective barrier method of birth control throughout the study and for up to 3 months following discontinuation of study drug * Careful rationalization with a view to discontinuing or considering alternatives to any concomitant medications that have potential to prolong the QT interval Exclusion Criteria: * Autologous transplant * Non-myeloablative transplant * Patient age \> 17 years with CML in first chronic phase * Aberrant antigen expression on marrow leukemic blasts \>= 5% by multidimensional flow cytometric assay immediately before conditioning (CML patients in chronic phase exempt from flow cytometry screening) * Ph+ ALL without complete cytogenetic remission immediately before conditioning * Known T315I mutation * Hypersensitivity to Gleevec or Tasigna * Patients who are Tasigna-resistant or intolerant * Central nervous system (CNS) involvement with leukemia at baseline (pre-imatinib therapy); CML chronic phase (CP), accelerated phase (AP) patients exempt from CNS involvement screening * Female patients who are pregnant, breast-feeding, or of childbearing potential without a negative serum pregnancy test at screening; male or female patients of childbearing potential unwilling to use effective contraceptive precautions throughout the trial; post-menopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential * Life expectancy severely limited by diseases other than leukemia * Myocardial infarction within one year prior to starting nilotinib * Other clinically significant heart disease (e.g. congestive heart failure, uncontrolled hypertension, unstable angina) * Absolute neutrophil count (ANC) less than 1500 per microliter at study entry despite the use of filgrastim (G-CSF) * Impaired cardiac function, including any one of the following: * Complete left bundle branch block or bifascicular block (right bundle branch block plus left anterior hemiblock) or use of ventricular-paced pacemaker * Congenital long QT syndrome or a family history of long QT syndrome * History of or presence of significant ventricular or atrial tachyarrhythmias * Clinically significant resting bradycardia (\< 50 beats per minute) * Corrected QT interval (QTc) \> 450 milliseconds on screening electrocardiogram (ECG); if QTc \> 450 and electrolytes are not within normal ranges, electrolytes should be corrected and then the patient rescreened for QTc
healthy Volunteers: false
sex: ALL
std Ages: CHILD
ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
Beginning after engraftment and blood count recovery (21 to 28 days after allogeneic stem cell transplant), patients with imatinib-sensitive leukemia receive imatinib mesylate PO QD until day 80 and then nilotinib PO BID on days 81-445. Patients with imatinib-resistant leukemia receive nilotinib PO BID beginning after engraftment and blood count recovery until day 445. Treatment continues in the absence of disease progression or unacceptable toxicity.
intervention Names
Drug: nilotinib
Drug: imatinib mesylate
Other: pharmacological study
label
Treatment (prophylactic inhibition of BCR-ABL tyrosine kinase)
type
EXPERIMENTAL

interventions

arm Group Labels
Treatment (prophylactic inhibition of BCR-ABL tyrosine kinase)
description
Given PO
name
nilotinib
other Names
AMN 107
Tasigna
type
DRUG
arm Group Labels
Treatment (prophylactic inhibition of BCR-ABL tyrosine kinase)
description
Given PO
name
imatinib mesylate
other Names
CGP 57148
Gleevec
Glivec
type
DRUG
arm Group Labels
Treatment (prophylactic inhibition of BCR-ABL tyrosine kinase)
description
Correlative studies
name
pharmacological study
other Names
pharmacological studies
type
OTHER

Study design

allocation

intervention Model

SINGLE_GROUP

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 40
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
Safety and tolerability of nilotinib therapy in patients with imatinib-sensitive leukemia graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events version 4.0. Treatment safety failure is defined for a patient with imatinib sensitive Ph+ leukemia as the inability to be able to deliver at least 400 milligrams per day of nilotinib in adults, and 230 milligrams/m2 per day in children, for at least 85% of the time interval between 81 and 365 days after transplant. The overall study will be considered successful if nilotinib is deliverable to more than 75% of the study participants at this minimum specified dose intensity.
measure
Number of Participants With Treatment Safety Failure
time Frame
Up to 365 days post-transplant

secondary Outcomes

description
To be considered a treatment efficacy success at 1 year posttransplant, the patient's bone marrow must demonstrate complete hematological remission, absence of Philadelphia chromosomes, and not satisfy any of the criteria for treatment failure (\>/= 1% aberrantly expressing marrow blasts by multiparameter flow cytometry, \>5% BCR/ABL in marrow by fluorescent in situ hybridization, or \>1 log rise in peripheral blood BCR/ABL by quantitative polymerase chain reaction (PCR) since day 80).
measure
The Proportion of Patients at 1 Year With Treatment Efficacy Success
time Frame
Up to 1 year
description
The proportion of study participants alive at 1, 2 and 3 years
measure
Survival
time Frame
Up to 3 years
description
The proportion of study participants alive and without hematologic, cytogenetic or molecular evidence of BCR/ABL-positive leukemia at 1 year
measure
Patients Alive With Out Relapse
time Frame
Up to 1 year
description
The proportion of patients with hematologic, cytogenetic or molecular relapse of BCR/ABL-positive leukemia
measure
Relapse
time Frame
1 and 3 years

Full study description

brief Summary: This phase I/II trial is studying the side effects and best way to give nilotinib when given alone or sequentially after imatinib mesylate after donor stem cell transplant in treating patients with acute lymphoblastic leukemia or chronic myelogenous leukemia. Nilotinib and imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
detailed Description: PRIMARY OBJECTIVES: I. To determine the safety of the administration of nilotinib between Day 81 and Day 365 after hematopoietic cell transplantation (HCT) in patients with Philadelphia chromosome positive (Ph+) leukemia. SECONDARY OBJECTIVES: I. To quantify the breakpoint cluster region (BCR)/Abelson murine leukemia (ABL) transcript load after HCT during tyrosine kinase inhibitor therapy in patients with Ph+ leukemia treated sequentially with imatinib (imatinib mesylate) and nilotinib from the time of engraftment. II. To evaluate survival at 1 year in patients with Ph+ leukemia who received sequential imatinib and nilotinib from the time of engraftment. III. To determine if imatinib can be co-administered with nilotinib for patients with rising levels of BCR/ABL on 2 consecutive occasions after HCT. IV. To confirm that imatinib can be delivered at an average daily dose of 400 mg at least 85% of the time in the majority of adults during the first 80 days after HCT. V. To determine whether nilotinib can be administered safely at a daily dose of at least 300 mg (175 mg/m\^2 in children \< 17 years) at least 70% of the time to patients with imatinib resistant Ph+ leukemia during the first 80 days after HCT. VI. To determine treatment efficacy success at 1 year post-transplant as demonstrated by complete hematological remission, absence of Philadelphia chromosome, and not satisfying any of the criteria for treatment failure. OUTLINE: Beginning after engraftment and blood count recovery (21-28 days after allogeneic stem cell transplant), patients with imatinib-sensitive leukemia receive imatinib mesylate orally (PO) once daily (QD) until day 80 and then nilotinib PO twice daily (BID) on days 81-445. Patients with imatinib-resistant leukemia receive nilotinib PO BID beginning after engraftment and blood count recovery until day 445. Treatment continues in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up periodically.

Source references

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-d3aa2da83bd0b7540f9d
requested nct id
NCT00702403
primary nct id
NCT00702403
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Childhood+Chronic+Myeloid+Leukemia&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
193739e64f77123de4344901c9970a0996a667fa587f14135380bef3ae38e11d
payload sha256
ef4c9c94ac646f0062050d11ae141f1de7fe3d9ac810ad8146871b8bc278fd9f
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-d3aa2da83bd0b7540f9d
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT00702403
occurrences
context exact
NCT00702403
end
11
exact text
NCT00702403
start
0
offset unit
unicode_code_points
query cond
Childhood Chronic Myeloid Leukemia
query disease state id
ds-chronic-myeloid-leukemia-pediatric
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-childhood-chronic-myeloid-leukemia-000.json
source file sha256
193739e64f77123de4344901c9970a0996a667fa587f14135380bef3ae38e11d
source json pointer
/studies/63/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
dd7203ed7583900fb215ff7525ddb0d49d7d214cd204a8e8f9026e39deb54993
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Childhood+Chronic+Myeloid+Leukemia&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true

Preserved source evidence · Not medical advice